FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Imfinzi OKd for Resectable Lung Cancer

AstraZeneca gains FDA approval for Imfinzi (durvalumab) with platinum-containing chemotherapy for adults with resectable non-small cell lung cancer.

latest-news-card-1
Human Drugs

Court Nixes Restraining Order Request in Entresto Suit

The Washington DC District Court rejects a Novartis motion in a generic drug carve-out case for a preliminary injunction to stay FDAs approval of MSN ...

latest-news-card-1
Federal Register

No-Longer-Marketed Enteregs Approval Withdrawn

Federal Register notice: FDA withdraws approval of Cubist Pharmaceuticals Entereg (alvimopan) capsules because it is no longer marketed.

latest-news-card-1
Federal Register

Regulatory Review Period for B+Ls Miebo

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Bausch + Lombs eye drug Miebo (perfluorohexyloc...

latest-news-card-1
Federal Register

FDA Debars Ryan Stabile for 15 Years

Federal Register notice: FDA debars Ryan Stabile for 15 years from importing or offering for import any drug into the U.S.

latest-news-card-1

More FDA Stringency Seen on Accelerated Drug OKs

Two Sheppard Mullin attorneys say sponsors of drugs approved through expedited pathways should learn from a recent FDA untitled letter faulting Mirais...

Medical Devices

FDA Clears Cresilons Traumagel

FDA clears Cresilons Traumagel device that uses a plant-based technology to control moderate to severe bleeding at the point of care.

latest-news-card-1
Human Drugs

FDA Touts CDER Advanced Manufacturing Research Facility

FDA describes CDERs new state-of-the-art advanced manufacturing research facility.

latest-news-card-1
Biologics

Priority Review for Imfinzi sBLA in Lung Cancer

FDA accepts for priority review an AstraZeneca supplemental BLA for Imfinzi (durvalumab) and its use in certain patients with limited-stage small cell...

latest-news-card-1
Human Drugs

Rare Disease Status Given to Duchenne Therapy

FDA grants Wave Life Sciences a rare pediatric disease designation for WVE-N531 and its use in treating boys with Duchenne muscular dystrophy.